Current evidence suggests that medicinal cannabis could be a less dangerous alternative to current drugs on the market.
Molecular and advanced functional imaging are to be used to compare the brain effects of placebo, THC, and CBD related to attention, memory, processing of novelty and change as well as stress and pain.
Study marks one of the first attempts by U.S. scientists to assess how cannabis with varying concentrations of THC and CBD affect medicinal cannabis users’ feelings of well-being when smoked outside of a laboratory.
The funding will support research to investigate whether medicinal cannabinoid therapies can alleviate symptoms in children with severe autism—and if so, how.
In a small pilot study, patients using high CBD strains exhibited lower levels of circulating cytokines a marker of inflammation often associated with pain - than those using higher THC products.
Dr. Dreismann is a top industry expert in the field of molecular and medical diagnostics and will support efforts to bring more exciting analytical tools into cannabis consumers' hands.
Findings underscore the importance of screening for cannabis use during prenatal care and the need for counseling about the adverse health consequences of continued use during pregnancy.